2-Deoxy-D-ribose hydrogel versus 5% minoxidil for androgenetic alopecia

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This randomized controlled study will enroll 60 adults with mild to moderate androgenetic alopecia and randomize them to either 2‑Deoxy‑D‑ribose (2dDR) hydrogel applied once daily or topical 5% minoxidil applied per sex-specific dosing for six months. Participants will undergo clinical exams, trichoscopy, and standardized scalp photography at baseline, Week 12, and Week 24 to document hair changes. Scalp biopsies will be taken at baseline and after three months to measure tissue VEGF as a potential mechanism of action. Safety and adverse events will be monitored throughout the treatment period.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adults aged 18 to 50 years.
* Male and female patients with androgenetic alopecia.
* Mild to moderate disease severity, defined as Hamilton-Norwood scale II to V in males and Ludwig scale I to II in females.
* Ability and willingness to provide written informed consent.

Exclusion Criteria:

* Other types of hair loss, including inflammatory or scarring alopecia.
* Psoriasis.
* Inflammatory scalp dermatoses.
* History of severe systemic disease, including renal, cardiovascular, or hepatic disease.
* Chemotherapy during the last 5 years.
* Pregnancy.
* Lactation.
* Bleeding disorders.

Where it's running

• Kasr El Aini Hospital
  Cairo, Cairo Governorate, Egypt Recruiting

Study contacts

• Study coordinator: Heba Ahmed
• Email: heba.a.abdelgayed@kasralainy.edu.eg
• Phone: +201016532351

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Dual treatment with KeraFactor and Revian LED for female pattern hair loss

  This study tests whether using a scalp-stimulating serum together with a Revian LED cap helps women with androgenic alopecia grow more hair than each treatment alone or placebo.

  Recruiting K. Kay Durairaj, MD, FACS, A Medical Corporation · Pasadena, California · NCT07810504

• Two hair supplements for men with androgenic alopecia

  This study tests two daily hair supplement formulations against placebo to see if they improve hair growth and perceived hair quality in men with mild to moderate androgenetic alopecia over 84 days.

  Recruiting at 6 sites Activ'inside · Rende, Cosenza and 5 other locations · NCT07806474

• JAK2 levels in balding and non-balding scalp before and after topical minoxidil

  This will test whether three months of topical minoxidil changes JAK2 protein levels in the scalps of adults (18–50) with mild to moderate androgenetic alopecia.

  Recruiting Kasr El Aini Hospital · Cairo, Cairo Governorate · NCT07563036

• TH07 topical treatment for male pattern hair loss

  This trial will test whether a new daily topical spray called TH07 helps men aged 18–49 with male pattern hair loss grow more hair than standard minoxidil or a placebo over 24 weeks.

  Recruiting Phase 3 Triple Hair Inc · Vancouver, British Columbia · NCT07435012

• Umbilical cord mesenchymal stem cell exosome treatment for male pattern hair loss in young men

  This trial will test whether injections of umbilical cord mesenchymal stem cell exosomes can regrow hair or slow hair loss in men aged 18–35 with androgenic alopecia compared with topical 5% minoxidil.

  Recruiting Phase 1/2 Shenzhen People's Hospital · Shenzhen, Guangdong · NCT07203599

• Autologous hair follicle secretome treatment for androgenic alopecia

  This will test whether injecting a person's own hair-follicle secretome into the scalp can help adults with androgenic alopecia grow thicker, denser hair.

  Recruiting Acorn Biolabs Inc. · West Hollywood, California · NCT07107841

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.